LAV | RoundOS

← Back to your selection

All recorded activity

Rounds participated in: 4
Confirmed lead rounds: —
New companies: 4
Funding in participating rounds: $265.2M

By stage

Seed1

Series A1

Series B1

Series C+1

By primary sector

Biotech4

By country

China2

United States2

Rounds

4 in all activity

May 18

Accro Bioscience

Develops novel therapeutics for immune mediated diseases

$50MSeries C

Role not disclosed

Apr 3

Syneron Bio

Develops intelligent platform-driven macrocyclic peptide drug discovery

$150MSeries B

Role not disclosed

Mar 18

Excalipoint Therapeutics

Develops next-generation T-cell engager therapies for cancer and autoimmune diseases

$27.7MSeed+

Role not disclosed

Jan 14

Caldera Therapeutics

Develops bispecific antibody CLD-423 for inflammatory bowel disease

$37.5MSeries A1

Role not disclosed

← Back to your selection

All recorded activity

Rounds participated in: 4
Confirmed lead rounds: —
New companies: 4
Funding in participating rounds: $265.2M

By stage

Seed1

Series A1

Series B1

Series C+1

By primary sector

Biotech4

By country

China2

United States2

Rounds

4 in all activity

May 18

Accro Bioscience

Develops novel therapeutics for immune mediated diseases

$50MSeries C

Role not disclosed

Apr 3

Syneron Bio

Develops intelligent platform-driven macrocyclic peptide drug discovery

$150MSeries B

Role not disclosed

Mar 18

Excalipoint Therapeutics

Develops next-generation T-cell engager therapies for cancer and autoimmune diseases

$27.7MSeed+

Role not disclosed

Jan 14

Caldera Therapeutics

Develops bispecific antibody CLD-423 for inflammatory bowel disease

$37.5MSeries A1

Role not disclosed